Lifecore Biomedical (NASDAQ:LFCR) Issues Earnings Results, Beats Expectations By $0.02 EPS

Lifecore Biomedical (NASDAQ:LFCR) posted its quarterly earnings results on Thursday. The company reported ($0.25) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.27) by $0.02, Zacks reports. Lifecore Biomedical had a net margin of 5.09% and a negative return on equity of 382.65%.

Lifecore Biomedical Price Performance

Shares of LFCR traded down $0.77 during mid-day trading on Thursday, reaching $6.66. 848,568 shares of the stock traded hands, compared to its average volume of 214,029. The company has a current ratio of 1.83, a quick ratio of 0.80 and a debt-to-equity ratio of 12.90. Lifecore Biomedical has a 1 year low of $3.68 and a 1 year high of $8.90. The company has a market cap of $245.27 million, a price-to-earnings ratio of 83.25 and a beta of 0.99. The firm has a fifty day moving average price of $6.96 and a 200 day moving average price of $5.77.

Wall Street Analyst Weigh In

Separately, Craig Hallum boosted their target price on Lifecore Biomedical from $8.00 to $10.00 and gave the stock a “buy” rating in a research note on Friday, November 22nd.

About Lifecore Biomedical

Lifecore Biomedical, Inc, together with its subsidiaries, operates as an integrated contract development and manufacturing organization in the United States and internationally. The company engages in the manufacturing of pharmaceutical-grade sodium hyaluronate (HA) in bulk form, as well as formulated and filled syringes and vials for injectable products used in treating a range of medical conditions and procedures.